Use of soluble pro(renin) receptor to treat metabolic disorders and related conditions

Abstract

Disclosed are methods of treating obesity or an obesity-related condition comprising administering an effective amount of soluble (pro)renin receptor (sPRR) to a subject that is obese or having an obesity-related condition. In some instances, obesity-related conditions can be, but are not limited to, steatosis, hyperglycemia, insulin resistance, chronic renal disease. Disclosed are methods of reducing body weight comprising administering an effective amount of sPRR to a subject in need thereof. Disclosed are methods of treating fatty liver in a subject comprising administering an effective amount of sPRR to a subject in need thereof. Disclosed are methods of treating a fluid and electrolyte disorder comprising administering an effective amount of sPRR to a subject diagnosed with a fluid and electrolyte disorder.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . A method of treating obesity or an obesity-related condition comprising administering an effective amount of soluble (pro)renin receptor (sPRR) to a subject that is obese or having an obesity-related condition. 
     
     
         5 . The method of  claim 4 , wherein the obesity-related condition is steatosis, hyperglycemia, insulin resistance, or chronic renal disease. 
     
     
         6 . A method of reducing body weight comprising administering an effective amount of soluble (pro)renin receptor (sPRR) to a subject in need thereof. 
     
     
         7 . (canceled) 
     
     
         8 . The method of  claim 4 , wherein administering an effective amount of sPRR comprises administering a vehicle carrying an effective amount of sPRR. 
     
     
         9 . The method of  claim 8 , wherein the vehicle is a nanoparticle. 
     
     
         10 . The method of  claim 9 , wherein the nanoparticle is a lipsome or polymer. 
     
     
         11 . The method of  claim 4 , wherein the sPRR is a fusion protein. 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . The method of  claim 4  further comprising administering a known therapeutic. 
     
     
         15 . The method of  claim 14 , wherein the known therapeutic is known to treat obesity or an obesity-related condition. 
     
     
         16 . The method of  claim 14 , wherein the known therapeutic is known to treat fatty liver. 
     
     
         17 . The method of  claim 14 , wherein the known therapeutic is known to reduce body weight. 
     
     
         18 . The method of  claim 4 , wherein the sPRR is wild type sPRR. 
     
     
         19 . The method of  claim 4 , wherein sPRR is 70-99% identical to wild type sPRR. 
     
     
         20 . The method of  claim 4 , wherein the sPRR is administered in an amount of 10-300 μg/kg/day. 
     
     
         21 . A method of treating a metabolic disorder comprising administering an effective amount of soluble (pro)renin receptor (sPRR) to a subject diagnosed with a fluid and electrolyte disorder. 
     
     
         22 . The method of  claim 21 , wherein the metabolic disorder is obesity, obesity-related conditions, fluid and electrolyte disorders, lipid disorders, diabetes mellitus, exercise-associated hyponatremia, metabolic myopathy, pancreatitis, pansteatitis, X-linked hypophosphatemia.